NCT05148000View on ClinicalTrials.gov

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

March 31, 2023

Study Completion Date

June 23, 2023

Conditions
Glabellar Frown LinesCanthal Lines
Interventions
BIOLOGICAL

QM1114-DP

QM1114-DP

Trial Locations (1)

10021

Galderma Research Site, New York

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT05148000 - Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines | Biotech Hunter | Biotech Hunter